In Depth 27 Mar 2024
Are new treatments for multiple sclerosis on the horizon?
As the wait for new multiple sclerosis treatments continue, here are some ongoing clinical trials that hold promise.
In Depth
- Latest Posts
In Depth 25 Mar 2024
Beyond Wegovy: Could Novo Nordisk’s new experimental weight loss pill be even better?
Discover how Novo Nordisk’s new experimental obesity pill, amycretin, could be even more efficient for weight loss than Wegovy.
In Depth 21 Mar 2024
Biotech in France: What’s holding back progress and how to move forward?
Explore the latest insights from France Biotech’s ‘Panorama France HealthTech’ report, uncovering key insights of the French biotech sector.
In Depth 20 Mar 2024
Are molecular glues the key to undruggable targets?
As more biopharmas get sticky with molecular glue developers and venture capital interest grows, here is a review of the field.
In Depth 18 Mar 2024
Will the US biotech funding surge trigger a renaissance in the global biotech industry?
After a couple of challenging years in biotech investment, the US leads the march for recovery. Delve into the specifics driving this uptick.
In Depth 14 Mar 2024
Rett syndrome: advances in gene therapy brings hope
Explore the latest advancements in treating Rett syndrome, a rare genetic disorder, including groundbreaking gene therapies and drug trials.
ADVERTISEMENT
ADVERTISEMENT
In Depth 13 Mar 2024
From LSD to healing minds: Where are we standing in psychedelic drug development?
Delve into the growing sector of psychedelic drug development to find out where we are coming from, and where we are standing in the field.
In Depth 11 Mar 2024
Biotech bankruptcies: what to expect in 2024 following a record year?
2023 broke the record for the highest number of biotech bankruptcies in a decade. Can biotechs mitigate the risk in 2024?
In Depth 7 Mar 2024
Can AbbVie’s legacy live beyond its once best-selling drug Humira?
The sales of AbbVie’s Humira, once a best-seller, have dropped. Now, with a new CEO announced, things are about to change for the company.
In Depth 6 Mar 2024
The biggest private biotech investments in February 2024
The companies BioAge Labs, Latigo Biotherapeutics, and Neurona Therapeutics bagged the biggest private biotech investments in February 2024.
In Depth 4 Mar 2024
ALS: how close are we to a cure?
Let us take a look at how the hunt for amyotrophic lateral sclerosis (ALS) drugs has advanced over the past few years.
In Depth 28 Feb 2024
Beyond fundraising: how do venture capitals build early-stage biotechs?
Venture capitals can help build early-stage biotech startups and boost innovation in the life science industry.
ADVERTISEMENT
